Publications by authors named "C Belge"
Objective: We aimed to explore the feasibility of an inverted-T upper hemisternotomy approach for pulmonary endarterectomy (PEA) and report the results after 17 cases.
Methods: PEA was conducted through a 7-cm skin incision using an inverted-T upper hemisternotomy across the third intercostal spaces. Cardiopulmonary bypass (CPB) was established through central arterial and percutaneous femoral dual-staged venous cannulation.
Background: We conducted a volume-outcome (V-O) meta-analysis of PEA procedures for chronic thromboembolic pulmonary hypertension (CTEPH), to objectively determine the minimum required annual case load that can define a high-volume centre.
Methods: Three electronic databases were systematically queried until May 1st, 2024. Centres were divided in volume tertiles (Ts).
Article Synopsis
- Pulmonary arterial hypertension (PAH) is a serious, rare illness that affects blood vessels in the lungs and can lead to heart failure and even death.
- Current treatments work on three main areas but don't cure the disease, so researchers are looking for new options.
- Sotatercept is a new medication that helps improve patients' health and quality of life, and it's been shown to be safe, though it can cause some side effects.
Article Synopsis
- Pulmonary arterial hypertension (PAH) is a rare disease linked to specific genetic variants, particularly in the BMPR2 gene and others that can increase susceptibility.
- Healthcare professionals are encountering questions about the value of genetic testing for PAH patients and their families, leading to the need for clear guidance and frameworks for genetic counseling.
- Benefits of molecular genetic testing include better diagnosis, improved patient management, and the identification of healthy carriers within families, which can enhance ongoing health monitoring.
Mutations in the () gene and signaling pathway impairment are observed in heritable and idiopathic pulmonary arterial hypertension (PAH). In PAH, endothelial dysfunction is currently handled by drugs targeting the endothelin-1 (ET-1), nitric oxide (NO), and prostacyclin (PGI) pathways. The role of angiogenesis in the disease process and the effect of PAH therapies on dysregulated angiogenesis remain inconclusive.
View Article and Find Full Text PDF